Pharmaceutical Technology2h
Aclaris Therapeutics secures global rights to Biosion’s antibodies
Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.
pharmaphorum6h
J&J plots filings after psoriasis drug clears phase 3 test
Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...
Santé log17h
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered ...